Back to search
FDAFDA · Food and drugs·Recall number D-1282-2022

Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60.

Published July 27, 2022 · Recall initiated: June 29, 2022

Summary

FDA records drug Class III recall D-1282-2022, published July 27, 2022 and initiated June 29, 2022. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Ongoing; Reported quantity: 168936 bottles; Lot: Lot#: 17201639, Exp 08/2022; 17201759, Exp 09/2022; 17202067, Exp 10/2022; 17210696, Exp 02/2023; 17210092, Exp 11/2022; 17210145, Exp 12/2022; 17210732, Exp 02/2023; 17211062, Exp 04/2023; 17211441, Exp 05/2023; 17211670, Exp 06/2023; 17211810, Exp 07/2023; 17211862, 17212020, 17212068, Exp 08/2023; 17212438, Exp 10/2023; 17220172, 17220251, Exp 12/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specification : Capsule breakage

What to do

Voluntary: Firm initiated · Letter

Get an email if ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Distributor
USA Nationwide
UPC
0368462405604
Lot
Lot#: 17201639, Exp 08/2022; 17201759, Exp 09/2022; 17202067, Exp 10/2022; 17210696, Exp 02/2023; 17210092, Exp 11/2022; 17210145, Exp 12/2022; 17210732, Exp 02/2023; 17211062, Exp 04/2023; 17211441, Exp 05/2023; 17211670, Exp 06/2023; 17211810, Exp 07/2023; 17211862, 17212020, 17212068, Exp 08/2023; 17212438, Exp 10/2023; 17220172, 17220251, Exp 12/2023.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60. recalled?

Yes. FDA published recall D-1282-2022 on July 27, 2022. Reported hazard: Failed Tablet/Capsule Specification : Capsule breakage

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE. UPC: 0368462405604.